glutamic acid has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bender, B; Closhen, D; Gerigk, M; Kuhlmann, CR; Lessmann, V; Luhmann, HJ | 1 |
1 other study(ies) available for glutamic acid and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
Article | Year |
---|---|
Fluvastatin prevents glutamate-induced blood-brain-barrier disruption in vitro.
Topics: Animals; Blood-Brain Barrier; Calcium; Cell Line; Dose-Response Relationship, Drug; Electric Impedance; Endothelial Cells; Fatty Acids, Monounsaturated; Fluvastatin; Glutamic Acid; Indoles; Intracellular Space; Myosin Light Chains; Nitric Oxide; Oxidative Stress; Phosphorylation; Rats; Reactive Oxygen Species; Receptors, N-Methyl-D-Aspartate; Signal Transduction; Time Factors | 2008 |